MedDataX Logo

A Study of MK-1084 Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

NCT ID: NCT06345729

Last Updated: 2025-11-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE3

Total Enrollment

600 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-05-24

Study Completion Date

2031-02-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a study evaluating the efficacy and safety of MK-1084 with pembrolizumab as first-line treatment in participants with locally advanced or metastatic non-small cell lung cancer (NSCLC) with identified Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C) mutation and programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%. There are two primary study hypotheses:

Hypothesis 1: Combination of MK-1084 and pembrolizumab is superior to placebo plus pembrolizumab with respect to progression free survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by blinded independent central review (BICR).

Hypothesis 2: Combination of MK-1084 plus pembrolizumab is superior to placebo plus pembrolizumab with respect to overall survival (OS).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Non-small Cell Lung Cancer

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Programmed Cell Death-1 (PD1, PD-1) Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2) Kirsten rat sarcoma viral oncogene homolog G12C (KRAS G12C)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MK-1084 with Pembrolizumab

Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles and MK-1084 by oral tablets until discontinuation criterion is met.

Group Type EXPERIMENTAL

MK-1084

Intervention Type DRUG

Oral tablets

Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Placebo with Pembrolizumab

Participants receive pembrolizumab 200 mg via intravenous (IV) infusion on Day 1 of each 21-day cycle (Q3W) for up to 35 cycles and placebo by oral tablets once daily until discontinuation criterion is met.

Group Type ACTIVE_COMPARATOR

Placebo

Intervention Type OTHER

Oral tablets

Pembrolizumab

Intervention Type BIOLOGICAL

IV infusion

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MK-1084

Oral tablets

Intervention Type DRUG

Placebo

Oral tablets

Intervention Type OTHER

Pembrolizumab

IV infusion

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

MK-3475 KEYTRUDA ®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Has histologically or cytologically confirmed diagnosis of non-small cell lung cancer (NSCLC)
* Has newly diagnosed Stage IIIB/IIIC NSCLC, not eligible for curative resection or curative chemotherapy/radiation as determined by a multidisciplinary tumor board and/or by radiation oncologist, surgeon, and medical oncologist or Stage IV (M1a, M1b, or M1c) by American Joint Committee on Cancer (AJCC) Staging Manual, Version 8
* Provides an archival tumor tissue sample (≤5 years) or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated to enable central laboratory testing of kirsten rat sarcoma (KRAS) G12C mutation status, PD-L1 status, and biomarker research
* If have had adverse events (AEs) due to previous anticancer therapies, must have recovered to \< Grade 1 or baseline
* If human immunodeficiency virus (HIV)-infected, must have well controlled HIV on antiretroviral therapy (ART)
* If Hepatitis B surface antigen (HBsAg) positive, have received Hepatitis B Virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load
* If a participant has a history of Hepatitis C virus (HCV) infection, HCV viral load is undetectable

Exclusion Criteria

* Has diagnosis of small cell lung cancer. For mixed tumors, if small cell elements are present, the participant is ineligible
* Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease
* Has known history of, or active, neurologic paraneoplastic syndrome
* Has an active infection requiring systemic therapy, with exceptions
* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
* Has one or more of the following ophthalmological findings/conditions: intraocular pressure \>21 mmHg and/or any diagnosis of glaucoma, diagnosis of central serous retinopathy, retinal vein occlusion, or retinal artery occlusion, diagnosis of retinal degenerative disease
* Has received prior systemic anticancer therapy for their locally advanced or metastatic NSCLC
* Has received radiation therapy to the lung that is \>30 Gray within 6 months of start of study intervention
* Has received radiotherapy within 2 weeks of start of study intervention. Participants must have recovered from all radiation-related toxicities, not required corticosteroids, and not have had radiation pneumonitis
* Has known active central nervous system metastases and/or carcinomatous meningitis
* Known additional malignancy that is progressing or has required active treatment within the past 3 years
* Has active autoimmune disease that has required systemic treatment in the past 2 years
* Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
* Is HIV-infected and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
* Has history of allogenic tissue/solid organ transplant
* Has not fully recovered from any effects of major surgical procedure
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Merck Sharp & Dohme LLC

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Medical Director

Role: STUDY_DIRECTOR

Merck Sharp & Dohme LLC

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

CBCC Global Research, Inc. ( Site 0123)

Bakersfield, California, United States

Site Status RECRUITING

Beverly Hills Cancer Center ( Site 0116)

Beverly Hills, California, United States

Site Status RECRUITING

Mount Sinai Cancer Center ( Site 0137)

Miami Beach, Florida, United States

Site Status RECRUITING

Orchard Healthcare Research Inc. ( Site 0115)

Skokie, Illinois, United States

Site Status RECRUITING

Truman Medical Center ( Site 0126)

Kansas City, Missouri, United States

Site Status RECRUITING

Cox Medical Center North ( Site 0133)

Springfield, Missouri, United States

Site Status RECRUITING

St. Vincent Frontier Cancer Center-Research ( Site 0105)

Billings, Montana, United States

Site Status RECRUITING

Atlantic Health System Morristown Medical Center ( Site 0121)

Morristown, New Jersey, United States

Site Status RECRUITING

New York Oncology Hematology, P.C. ( Site 0132)

Albany, New York, United States

Site Status RECRUITING

University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103)

Cincinnati, Ohio, United States

Site Status RECRUITING

Kettering Health Main Campus-Kettering Health Cancer Center ( Site 0106)

Kettering, Ohio, United States

Site Status RECRUITING

Lancaster General Hospital - Ann B Barshinger Cancer Institute ( Site 0134)

Lancaster, Pennsylvania, United States

Site Status RECRUITING

Oncology Consultants P.A. ( Site 0113)

Houston, Texas, United States

Site Status RECRUITING

Circuit Clinical/SSM Health Dean Medical Group ( Site 0129)

Madison, Wisconsin, United States

Site Status RECRUITING

AUSTRAL MEDICAL CENTER ( Site 0302)

CABA, Buenos Aires, Argentina

Site Status COMPLETED

Centro Oncologico Korben ( Site 0304)

CABA, Buenos Aires, Argentina

Site Status RECRUITING

Instituto de Investigaciones Clínicas Mar del Plata ( Site 0300)

Mar del Plata, Buenos Aires, Argentina

Site Status RECRUITING

Sanatorio Parque ( Site 0301)

Rosario, Santa Fe Province, Argentina

Site Status RECRUITING

Fundacion Estudios Clinicos ( Site 0306)

Rosario, Santa Fe Province, Argentina

Site Status RECRUITING

Chris O'Brien Lifehouse ( Site 3000)

Camperdown, New South Wales, Australia

Site Status RECRUITING

Frankston Hospital ( Site 3002)

Frankston, Victoria, Australia

Site Status RECRUITING

One Clinical Research ( Site 3001)

Nedlands, Western Australia, Australia

Site Status RECRUITING

Medizinische Universität Graz-Klinische Abteilung für Pulmonologie ( Site 2401)

Graz, Styria, Austria

Site Status RECRUITING

Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2400)

Vienna, , Austria

Site Status RECRUITING

Hospital Mario Penna ( Site 0436)

Belo Horizonte, Minas Gerais, Brazil

Site Status RECRUITING

Hospital de Câncer de Recife ( Site 0447)

Recife, Pernambuco, Brazil

Site Status RECRUITING

Oncoclínica Oncologistas Associados ( Site 0441)

Teresina, Piauí, Brazil

Site Status RECRUITING

Liga Norte Riograndense Contra o Câncer ( Site 0439)

Natal, Rio Grande do Norte, Brazil

Site Status RECRUITING

Irmandade da Santa Casa de Misericórdia de Porto Alegre-Centro Multidisciplinar de Pesquisa Clínica ( Site 0435)

Porto Alegre, Rio Grande do Sul, Brazil

Site Status RECRUITING

Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica ( Site 0437)

Barretos, São Paulo, Brazil

Site Status RECRUITING

Instituto Nacional de Câncer - INCA ( Site 0446)

Rio de Janeiro, , Brazil

Site Status RECRUITING

Americas ( Site 0431)

Rio de Janeiro, , Brazil

Site Status RECRUITING

MBAL Uni Hospital-Department of Medical Oncology ( Site 1000)

Panagyurishte, Pazardzhik, Bulgaria

Site Status RECRUITING

Multiprofile Hospital for Active Treatment SerdikaМЕD EOOD-Second Department of Medical Oncology ( Site 1002)

Sofia, Sofia (stolitsa), Bulgaria

Site Status RECRUITING

MHAT - Heart and Brain ( Site 1006)

Pleven, , Bulgaria

Site Status RECRUITING

CancerCare Manitoba ( Site 0210)

Winnipeg, Manitoba, Canada

Site Status RECRUITING

QEII Health Sciences Centre - Victoria General Site-Dept. of Medical Oncology ( Site 0208)

Halifax, Nova Scotia, Canada

Site Status RECRUITING

Hamilton Health Sciences-Juravinski Cancer Centre ( Site 0205)

Hamilton, Ontario, Canada

Site Status RECRUITING

Sunnybrook Research Institute ( Site 0206)

Toronto, Ontario, Canada

Site Status RECRUITING

St. Marys Hospital Center ( Site 0204)

Montreal, Quebec, Canada

Site Status RECRUITING

Centre integre universitaire de sante et de services sociaux de la Mauricie-et-du-centre-du-quebec ( Site 0207)

Trois-Rivières, Quebec, Canada

Site Status RECRUITING

Clinica Universidad Catolica del Maule-Oncology ( Site 0500)

Talca, Maule Region, Chile

Site Status RECRUITING

Orlandi Oncologia-Oncology ( Site 0503)

Santiago, Region M. de Santiago, Chile

Site Status RECRUITING

FALP-UIDO ( Site 0501)

Santiago, Region M. de Santiago, Chile

Site Status RECRUITING

Centro de Oncología de Precisión-Oncology ( Site 0502)

Santiago, Region M. de Santiago, Chile

Site Status RECRUITING

Bradfordhill-Clinical Area ( Site 0504)

Santiago, Region M. de Santiago, Chile

Site Status RECRUITING

Anhui Provincial Cancer Hospital ( Site 3136)

Hefei, Anhui, China

Site Status RECRUITING

Beijing Cancer hospital ( Site 3133)

Beijing, Beijing Municipality, China

Site Status RECRUITING

Beijing Cancer hospital ( Site 3134)

Beijing, Beijing Municipality, China

Site Status RECRUITING

Beijing Peking Union Medical College Hospital-pneumology department ( Site 3102)

Beijing, Beijing Municipality, China

Site Status RECRUITING

Beijing Chest Hospital,Capital Medical University ( Site 3104)

Beijing, Beijing Municipality, China

Site Status RECRUITING

Chongqing University Cancer Hospital ( Site 3119)

Chongqing, Chongqing Municipality, China

Site Status RECRUITING

Army Medical Center of People's Liberation Army ( Site 3142)

Chongqing, Chongqing Municipality, China

Site Status RECRUITING

Fujian Cancer Hospital ( Site 3127)

Fuzhou, Fujian, China

Site Status RECRUITING

The First Affiliated hospital of Xiamen University ( Site 3148)

Xiamen, Fujian, China

Site Status RECRUITING

The First Affiliated Hospital of Guangzhou Medical University ( Site 3108)

Guangzhou, Guangdong, China

Site Status RECRUITING

Southern Medical University Nanfang Hospital ( Site 3128)

Guangzhou, Guangdong, China

Site Status RECRUITING

Sun Yat-sen University Cancer Center ( Site 3137)

Guangzhou, Guangdong, China

Site Status RECRUITING

Harbin Medical University Cancer Hospital ( Site 3123)

Harbin, Heilongjiang, China

Site Status RECRUITING

JIAMUSI TUBERCULOSIS HOSPITAL(CANCER HOSPITAL) ( Site 3124)

Jiamusi, Heilongjiang, China

Site Status RECRUITING

Henan Cancer Hospital ( Site 3149)

Zhengzhou, Henan, China

Site Status RECRUITING

Tongji Hospital Tongji Medical,Science & Technology ( Site 3113)

Wuhan, Hubei, China

Site Status RECRUITING

Hubei Cancer Hospital ( Site 3126)

Wuhan, Hubei, China

Site Status RECRUITING

The Second Xiangya Hospital of Central South University ( Site 3130)

Changsha, Hunan, China

Site Status RECRUITING

Hunan Cancer Hospital ( Site 3141)

Changsha, Hunan, China

Site Status RECRUITING

Nanjing Gulou Hospital ( Site 3122)

Nanjing, Jiangsu, China

Site Status RECRUITING

Nanjing First Hospital ( Site 3154)

Nanjing, Jiangsu, China

Site Status RECRUITING

The First Affiliated Hospital of Soochow University ( Site 3146)

Suzhou, Jiangsu, China

Site Status RECRUITING

Affiliated Hospital of Jiangnan University(Wuxi Fourth People's Hospital ) ( Site 3155)

Wuxi, Jiangsu, China

Site Status RECRUITING

The Second Affiliated Hospital of Nanchang University ( Site 3139)

Nanchang, Jiangxi, China

Site Status RECRUITING

The First affiliated hospital of Nanchang University (Xianghu campus) ( Site 3138)

Nanchang, Jiangxi, China

Site Status RECRUITING

Jilin Province Tumor Hospital ( Site 3107)

Changchun, Jilin, China

Site Status RECRUITING

The First Affiliated Hospital of Xi'an Jiaotong University ( Site 3150)

Xi'an, Shaanxi, China

Site Status RECRUITING

Shandong Cancer Hospital ( Site 3116)

Jinan, Shandong, China

Site Status RECRUITING

LinYi Cancer Hospital ( Site 3111)

Linyi, Shandong, China

Site Status RECRUITING

Shanghai Chest Hospital ( Site 3100)

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Fudan University Shanghai Cancer Center ( Site 3144)

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Zhongshan Hospital,Fudan University ( Site 3143)

Shanghai, Shanghai Municipality, China

Site Status RECRUITING

Shanxi Cancer Hospital ( Site 3131)

Taiyuan, Shanxi, China

Site Status RECRUITING

The Second Affiliated Hospital of Air Force Medical University ( Site 3117)

Xian, Shanxi, China

Site Status RECRUITING

The Second Affiliated Hospital of Air Force Medical University ( Site 3152)

Xian, Shanxi, China

Site Status RECRUITING

The Third People's Hospital of Chengdu (CDTPH) ( Site 3157)

Chengdu, Sichuan, China

Site Status RECRUITING

West China Hospital, Sichuan University ( Site 3140)

Chengdu, Sichuan, China

Site Status RECRUITING

Sichuan Cancer hospital. ( Site 3109)

Chengdu, Sichuan, China

Site Status RECRUITING

The Second People's Hospital of Neijiang ( Site 3105)

Neijiang, Sichuan, China

Site Status RECRUITING

Xinjiang Medical University Cancer Hospital - Urumqi ( Site 3101)

Ürümqi, Xinjiang, China

Site Status RECRUITING

Yunnan Province Cancer Hospital ( Site 3153)

Kunming, Yunnan, China

Site Status RECRUITING

The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3115)

Hangzhou, Zhejiang, China

Site Status RECRUITING

Sir Run Run Shaw Hospital of Zhejiang University School of Medicine ( Site 3121)

Hangzhou, Zhejiang, China

Site Status RECRUITING

Taizhou Hospital of Zhejiang Province ( Site 3145)

Linhai, Zhejiang, China

Site Status RECRUITING

The First Affiliated Hospital of Wenzhou Medical University ( Site 3151)

Wenzhou, Zhejiang, China

Site Status RECRUITING

Centre Hospitalier Universitaire Dijon Bourgogne - Hôpital François Mitterrand ( Site 1103)

Dijon, Bourgogne-Franche-Comté, France

Site Status RECRUITING

Clinique Teissier Groupe ( Site 1100)

Valenciennes, Nord, France

Site Status RECRUITING

Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne-ONCOLOGY ( Site 1101)

Clermont-Ferrand, Puy-de-Dome, France

Site Status RECRUITING

Centre Hospitalier d'Avignon-Service d'Oncologie médicale et d'hématologie clinique ( Site 1104)

Avignon, Vaucluse, France

Site Status RECRUITING

Hôpital Ambroise Paré-Department of Respiratory Diseases and Thoracic Oncology ( Site 1105)

Boulogne-Billancourt, Île-de-France Region, France

Site Status RECRUITING

High Technology Hospital Medcenter ( Site 1203)

Batumi, Adjara, Georgia

Site Status RECRUITING

Caucasus Medical Centre ( Site 1202)

Tbilisi, Adjara, Georgia

Site Status RECRUITING

American Hospital Network LLC ( Site 1208)

Tbilisi, , Georgia

Site Status RECRUITING

Todua Clinic, LLC ( Site 1204)

Tbilisi, , Georgia

Site Status RECRUITING

TSMU and Ingorokva High Medical Technology University Clinic LTD ( Site 1201)

Tbilisi, , Georgia

Site Status RECRUITING

New Hospitals ( Site 1200)

Tbilisi, , Georgia

Site Status RECRUITING

Cancer Research Centre. Mardaleishvili Medical Centre ( Site 1205)

Tbilisi, , Georgia

Site Status RECRUITING

Tbilisi Institute of Medicine ( Site 1206)

Tbilisi, , Georgia

Site Status RECRUITING

Marienhospital Stuttgart ( Site 1302)

Stuttgart, Baden-Wurttemberg, Germany

Site Status RECRUITING

Krankenhaus Bethanien ( Site 1303)

Solingen, North Rhine-Westphalia, Germany

Site Status RECRUITING

UNIVERSITY HOSPITAL OF PATRAS-DIVISION OF ONCOLOGY ( Site 1402)

Pátrai, Achaia, Greece

Site Status RECRUITING

THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 1400)

Athens, Attica, Greece

Site Status RECRUITING

University General Hospital of Larissa-Oncology Clinic ( Site 1403)

Larissa, Thessaly, Greece

Site Status RECRUITING

Agios Loukas Clinic ( Site 1404)

Thessaloniki, , Greece

Site Status RECRUITING

G. Papanikolaou General Hospital-Pulmonary Clinic of Aristotle University of Thessaloniki ( Site 1405)

Thessaloniki, , Greece

Site Status RECRUITING

Istituto Nazionale Tumori IRCCS Fondazione Pascale-Oncologia clinica sperimentale Toraco-Polmonare ( Site 1607)

Napoli, Campania, Italy

Site Status RECRUITING

Ospedale Santa Maria delle Croci ( Site 1606)

Ravenna, Emilia-Romagna, Italy

Site Status RECRUITING

CRO-IRCCS-Clinical Oncology ( Site 1605)

Aviano, Friuli Venezia Giulia, Italy

Site Status RECRUITING

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -Medical Oncology ( Site 1601)

Rome, Lazio, Italy

Site Status RECRUITING

Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 1600)

Milan, Lombardy, Italy

Site Status RECRUITING

Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 1604)

Milan, Lombardy, Italy

Site Status RECRUITING

A.O.R.N. Ospedale dei Colli - Monaldi V.-U.O.C Pneumologia Oncologica DH PNL ONC ( Site 1602)

Naples, Napoli, Italy

Site Status RECRUITING

Istituto Nazionale Tumori Regina Elena-Oncologia Medica 2 ( Site 1609)

Rome, Roma, Italy

Site Status RECRUITING

Azienda USL Toscana Nord Ovest_Ospedale Civile di Livorno-UOC Oncologia Medica Livorno ( Site 1608)

Livorno, Tuscany, Italy

Site Status RECRUITING

IOV - Istituto Oncologico Veneto IRCCS UOSD - Unità di ricerca clinica ( Site 1603)

Padua, , Italy

Site Status RECRUITING

Nagoya University Hospital ( Site 3309)

Nagoya, Aichi-ken, Japan

Site Status RECRUITING

Fujita Health University Hospital ( Site 3310)

Toyoake, Aichi-ken, Japan

Site Status RECRUITING

National Hospital Organization Shikoku Cancer Center ( Site 3315)

Matsuyam, Ehime, Japan

Site Status RECRUITING

National Hospital Organization Kyushu Cancer Center ( Site 3316)

Fukuoka, Fukuoka, Japan

Site Status RECRUITING

Kurume University Hospital ( Site 3317)

Kurume, Fukuoka, Japan

Site Status RECRUITING

Gunma Prefectural Cancer Center ( Site 3302)

Ōta, Gunma, Japan

Site Status RECRUITING

Kanazawa University Hospital ( Site 3308)

Kanazawa, Ishikawa-ken, Japan

Site Status RECRUITING

St. Marianna University Hospital ( Site 3320)

Kawasaki, Kanagawa, Japan

Site Status RECRUITING

Matsusaka Municipal Hospital ( Site 3311)

Matsusaka, Mie-ken, Japan

Site Status RECRUITING

Miyagi Cancer Center ( Site 3301)

Natori-shi, Miyagi, Japan

Site Status RECRUITING

Sendai Kousei Hospital ( Site 3300)

Sendai, Miyagi, Japan

Site Status RECRUITING

Kansai Medical University Hospital ( Site 3312)

Hirakata, Osaka, Japan

Site Status RECRUITING

Osaka Medical and Pharmaceutical University Hospital ( Site 3313)

Takatsuki, Osaka, Japan

Site Status RECRUITING

Saitama Prefectural Cancer Center ( Site 3304)

Kitaadachi-gun, Saitama, Japan

Site Status RECRUITING

Nippon Medical School Hospital ( Site 3306)

Bunkyo, Tokyo, Japan

Site Status RECRUITING

Toho University Omori Medical Center ( Site 3319)

Ōta-ku, Tokyo, Japan

Site Status RECRUITING

Tokyo Medical University Hospital ( Site 3307)

Shinjuku, Tokyo, Japan

Site Status RECRUITING

National Center for Global Health and Medicine ( Site 3305)

Shinjuku, Tokyo, Japan

Site Status RECRUITING

Chiba University Hospital ( Site 3322)

Chiba, , Japan

Site Status RECRUITING

Hiroshima City Hiroshima Citizens Hospital ( Site 3314)

Hiroshima, , Japan

Site Status RECRUITING

Saiseikai Kumamoto Hospital ( Site 3318)

Kumamoto, , Japan

Site Status RECRUITING

Osaka Metropolitan University Hospital ( Site 3321)

Osaka, , Japan

Site Status RECRUITING

Arké SMO S.A. de C.V. ( Site 0602)

Mexico City, Mexico City, Mexico

Site Status RECRUITING

Hospital Universitario "Dr. Jose Eleuterio Gonzalez"-Hematologia and Oncologia ( Site 0600)

Monterrey, Nuevo León, Mexico

Site Status RECRUITING

Oaxaca Site Management Organization S.C. ( Site 0603)

Oaxaca City, , Mexico

Site Status RECRUITING

Ziekenhuis Gelderse Vallei ( Site 1705)

Ede, Gelderland, Netherlands

Site Status RECRUITING

Ziekenhuis St. Jansdal-Poli Longziekten ( Site 1701)

Harderwijk, Gelderland, Netherlands

Site Status RECRUITING

Isala, locatie Zwolle-Poli Longziekten ( Site 1700)

Zwolle, Overijssel, Netherlands

Site Status RECRUITING

Universitair Medisch Centrum Utrecht ( Site 1704)

Utrecht, , Netherlands

Site Status RECRUITING

Auckland City Hospital ( Site 3400)

Auckland, , New Zealand

Site Status RECRUITING

Lung Center of the Philippines-Pulmonary, Critical Care and Sleep Medicine ( Site 3503)

Quezon City, National Capital Region, Philippines

Site Status RECRUITING

Veterans Memorial Medical Center-Section of Oncology ( Site 3505)

Quezon City, National Capital Region, Philippines

Site Status RECRUITING

Szpital Specjalistyczny im. Henryka Klimontowicza ( Site 1801)

Gorlice, Lesser Poland Voivodeship, Poland

Site Status RECRUITING

Pratia MCM Krakow ( Site 1808)

Krakow, Lesser Poland Voivodeship, Poland

Site Status RECRUITING

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 1800)

Warsaw, Masovian Voivodeship, Poland

Site Status RECRUITING

Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1804)

Przemyśl, Podkarpackie Voivodeship, Poland

Site Status RECRUITING

Centrul de Oncologie Sfantul Nectarie-Medical ( Site 1994)

Craiova, Dolj, Romania

Site Status RECRUITING

Cabinet Medical Oncomed ( Site 1998)

Timișoara, Timiș County, Romania

Site Status RECRUITING

SC ONCO CARD SRL ( Site 1995)

Brasov, , Romania

Site Status RECRUITING

Institutul Oncologic Cluj-Oncologie Medicala ( Site 1999)

Cluj-Napoca, , Romania

Site Status RECRUITING

Sigmedical Services SRL ( Site 1997)

Suceava, , Romania

Site Status RECRUITING

The Catholic University of Korea, Incheon St. Mary's Hospital ( Site 3606)

Bupyeong-gu, Incheon, South Korea

Site Status RECRUITING

Chonnam National University Hwasun Hospital-Pulmonology ( Site 3604)

Hwasun, Jeonranamdo, South Korea

Site Status RECRUITING

The Catholic University Of Korea St. Vincent's Hospital-Medical Oncology ( Site 3600)

Suwon, Kyonggi-do, South Korea

Site Status RECRUITING

Pusan National University Yangsan Hospital-Lung Cancer Clinic ( Site 3603)

Yangsan, Kyongsangnam-do, South Korea

Site Status RECRUITING

Chungnam national university hospital ( Site 3602)

Junggu, Taejon-Kwangyokshi, South Korea

Site Status RECRUITING

Kyung Hee University Hospital ( Site 3605)

Seoul, , South Korea

Site Status RECRUITING

Korea University Guro Hospital ( Site 3601)

Seoul, , South Korea

Site Status RECRUITING

Hospital Insular de Gran Canaria-Oncology ( Site 2019)

Las Palmas de Gran Canaria, Las Palmas, Spain

Site Status RECRUITING

HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑON-ONCOLOGY ( Site 2012)

Madrid, Madrid, Comunidad de, Spain

Site Status RECRUITING

H.R.U Málaga - Hospital General-Oncology ( Site 2014)

Málaga, Malaga, Spain

Site Status RECRUITING

Hospital Universitari Vall d Hebron ( Site 2010)

Barcelona, , Spain

Site Status RECRUITING

Hospital Universitario Fundación Jiménez Díaz-Oncology & Hematology ( Site 2017)

Madrid, , Spain

Site Status RECRUITING

Hospital Universitario Virgen Macarena-Unidad de Investigación Oncológica ( Site 2015)

Seville, , Spain

Site Status RECRUITING

Ege Universitesi Hastanesi-Chest Diseases Department ( Site 2102)

Bornova, İzmir, Turkey (Türkiye)

Site Status RECRUITING

Adana Medical Park Seyhan Hastanesi-Medikal Onkoloji ( Site 2107)

Adana, , Turkey (Türkiye)

Site Status RECRUITING

SBU GULHANE EGITIM VE ARASTIRMA HASTANESI Onkoloji ( Site 2104)

Ankara, , Turkey (Türkiye)

Site Status RECRUITING

Hacettepe Universite Hastaneleri-oncology hospital ( Site 2101)

Ankara, , Turkey (Türkiye)

Site Status RECRUITING

Memorial Ankara Hastanesi-Medical Oncology ( Site 2106)

Ankara, , Turkey (Türkiye)

Site Status RECRUITING

Ankara Bilkent Şehir Hastanesi ( Site 2100)

Ankara, , Turkey (Türkiye)

Site Status RECRUITING

Medipol Mega Universite Hastanesi-oncology ( Site 2105)

Istanbul, , Turkey (Türkiye)

Site Status RECRUITING

TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 2103)

Istanbul, , Turkey (Türkiye)

Site Status RECRUITING

COMMUNAL NONPROFIT ENTERPRISE "CLINICAL CENTER OF ONCOLOGY, HEMATOLOGY, TRANSPLANTOLOGY AND PALLIATI ( Site 2209)

Cherkasy, Cherkasy Oblast, Ukraine

Site Status RECRUITING

Regional Municipal Non-profit Enterprise "Bukovinian Clinica-structural unit of the clinical trials ( Site 2210)

Chernivtsi, Chernivetska Oblast, Ukraine

Site Status RECRUITING

Medical Center "Mriya Med-Service"-Clinical Research Department ( Site 2215)

Kryvyi Rih, Dnipropetrovsk Oblast, Ukraine

Site Status RECRUITING

Communal Non-Commercial Enterprise "Prykarpatski Clinical On-Surgery department #2 ( Site 2202)

Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine

Site Status RECRUITING

Kirovohrad Regional Oncology Center-Chemotherapy department ( Site 2204)

Kropyvnytskyi, Kirovohrad Oblast, Ukraine

Site Status RECRUITING

Medical Center "MedOffice Group" ( Site 2219)

Kiev, Kyivska Oblast, Ukraine

Site Status RECRUITING

Municipal non-profit enterprise "Lviv Territorial Medical Union "Multidisciplinary Clinical Hospital ( Site 2217)

Lviv, Lviv Oblast, Ukraine

Site Status RECRUITING

Rivne Regional Clinical Hospital ( Site 2205)

Rivne, Rivne Oblast, Ukraine

Site Status COMPLETED

ME RIVNE REGIONAL ANTITUMOR CENTER ( Site 2920)

Rivne, Rivne Oblast, Ukraine

Site Status RECRUITING

Communal Noncommercial Enterprise "Podillia Regional Oncolog-Cardiothoracic department ( Site 2211)

Vinnytsia, Vinnytsia Oblast, Ukraine

Site Status RECRUITING

ME Volyn Regional Clinical Hospital of the Volyn Regional Council ( Site 2216)

Lutsk, Volyn Oblast, Ukraine

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

United States Argentina Australia Austria Brazil Bulgaria Canada Chile China France Georgia Germany Greece Italy Japan Mexico Netherlands New Zealand Philippines Poland Romania South Korea Spain Turkey (Türkiye) Ukraine

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Toll Free Number

Role: CONTACT

Phone: 1-888-577-8839

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Study Coordinator

Role: primary

Related Links

Access external resources that provide additional context or updates about the study.

https://www.merckclinicaltrials.com/

Merck Clinical Trials Information

https://msd.trialsummaries.com/Study/StudyDetails?id=26314&tenant=MT_MSD_9011

Plain Language Summary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MK-1084-004

Identifier Type: OTHER

Identifier Source: secondary_id

U1111-1296-8093

Identifier Type: REGISTRY

Identifier Source: secondary_id

2023-507776-42-00

Identifier Type: REGISTRY

Identifier Source: secondary_id

jRCT2031240213

Identifier Type: REGISTRY

Identifier Source: secondary_id

PHRR241128-007796

Identifier Type: REGISTRY

Identifier Source: secondary_id

KANDLELIT-004

Identifier Type: OTHER

Identifier Source: secondary_id

1084-004

Identifier Type: -

Identifier Source: org_study_id